Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations

NEWPORT BEACH, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program.

"David brings more than 25 years of investor relations and healthcare industry experience to this position, which will benefit Evolus as we continue to grow our global footprint, including our European launch expected in early 2022," said Lauren Silvernail, Evolus' Chief Financial Officer and Executive Vice President, Corporate Development. "His reputation and extensive relationships with the financial community will be incredibly helpful in driving value for Evolus, its shareholders and other key stakeholders."

Prior to joining Evolus, David served as Vice President, Investor Relations, Corporate Communications and Corporate Social Responsibility for Establishment Labs Holdings, a global medical technology and aesthetics company. Before that, he was Vice President, Investor Relations for Edwards Lifesciences, the global leader of patient-focused innovations for structural heart disease and critical care monitoring. David has also served in national and local chapter leadership roles for NIRI, The Association for Investor Relations, and was named a NIRI Fellow.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words "plans," "expects," "believes," "strategy," "opportunity," "anticipates," "outlook," "designed," or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The company's forward-looking statements include, but are not limited to, statements made by Mrs. Silvernail regarding the growth of the company's global footprint and the planned European launch for early 2022. Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to address all of our losses, costs, expenses, liabilities and damages resulting from the settlement agreement with Daewoong and our ability to comply with the terms and conditions in the Allergan/Medytox Settlement Agreements, including the effect on our pricing, discounts we may offer to our customers and the volume of purchases by our customers, the continued impact of COVID-19 on our business and the economy generally, uncertainties related to customer and consumer adoption of Jeuveau®, the efficiency and operability of our digital platform, competition and market dynamics, and our ability to maintain regulatory approval of Jeuveau® and other risks described in the section entitled "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on May 12, 2021, which is available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Evolus undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If the company does update or revise one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd

Evolus, Inc. Contacts:

Investor Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: +1-949-966-1798

Email: [email protected]

Media Contact:

Crystal Muilenburg, Evolus, Inc.

Chief Marketing Officer

Tel: +1-949-284-4506

Email: [email protected]